Citi Upgrades Ultragenyx Pharma (RARE) to Neutral
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $25.61 --0%
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 25
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 25
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz upgraded Ultragenyx Pharma (NASDAQ: RARE) from Sell to Neutral with a price target of $54.00 (from $46.00).
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $53.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James
- Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies
- Goldman Sachs Downgrades Mitsubishi Gas Chemical Co Inc (4182:JP) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
